Trastuzumab emtansine

Molecular mass: 973.556 g/mol

Therapeutic indications

Trastuzumab emtansine is indicated for:

HER2-positive breast cancer

Population group: only adults (18 years old or older)

Early Breast Cancer (EBC)

Trastuzumab emtansine, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

Metastatic Breast Cancer (MBC)

Trastuzumab emtansine, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:

Received prior therapy for locally advanced or metastatic disease, or
Developed disease recurrence during or within six months of completing adjuvant therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.6 mg/kg once every 3 weeks

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.